Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | NCF1 | P14598 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623594 | 1.00 | HTR2C (0.65) | HTR2CADRB2NCF1EPHX2CYP3A4 | |
| SCHEMBL3690249 | 0.81 | HRH4 (0.65) | CYP3A4KDM4ECYP1A2TSHR | |
| SCHEMBL22050038 | 0.81 | PTK2 (0.65) | CYP3A4KDM4ECYP1A2TSHR | |
| SCHEMBL30040877 | 0.79 | HTR2C (1.00) | HTR2CADRB2NCF1KDM4ECYP1A2 | |
| SCHEMBL2076366 | 0.79 | HTR2C (1.00) | HTR2CADRB2NCF1KDM4ECYP1A2 | |
| SCHEMBL1029331 | 0.79 | PTK2 (0.67) | HTR2CADRB2NCF1CYP3A4KDM4E | |
| SCHEMBL29936658 | 0.79 | PTK2 (0.67) | HTR2CADRB2NCF1CYP3A4KDM4E | |
| SCHEMBL17844894 | 0.78 | AKT2 (0.47) | HTR2CKDM4E | |
| SCHEMBL3689345 | 0.78 | PRKD1 (0.52) | HTR2CADRB2NCF1EPHX2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1532881 | 0.77 | HTR2C (0.97) | HTR2CADRB2NCF1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-108026080-B | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| CN-106255689-B | Heteroaryl SYK Inhibitors | 勃林格殷格翰国际有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110183440-A | Heteroaryl SYK inhibitor | 勃林格殷格翰国际有限公司 | 2019-08-30 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003057695-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR2C 14/4885ADRB2 61/4885NCF1 1250/4885 |
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | HTR2C 3171/4885ADRB2 2101/4885NCF1 169/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | HTR2C 897/4885ADRB2 1410/4885NCF1 161/4885 |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | HTR2C 109/4885ADRB2 456/4885NCF1 3910/4885 |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | HTR2C 3171/4885ADRB2 2101/4885NCF1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.